Study Condition(s): Mild Alzheimer's, Mild Cognitive Impairment

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Participants With Early Alzheimer's Disease (AMARANTH)

Study Alias: AZES

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02245737 {{ currentLocaleObject.registryAnchorText }}

Withdrawn Active, not recruiting

Study Purpose

The purpose of this study is to assess the efficacy and safety of LY3314814 compared with placebo in the treatment of early Alzheimer's disease.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


55 years
85 years

Time Commitment

Your participation could last approximately 2 years and include 21 visits to the study center.
  • Participant must have experienced gradual and progressive change in memory function for longer than 6 months or have been diagnosed with mild Alzheimer's disease or mild cognitive impairment

  • Participant must have a close friend, relative, or partner who is in regular contact and who would be willing to be a study partner throughout the study (for example, attend all study appointments and answer questions about the participant on the telephone)

  • Participant must not have significant neurological disease (such as Parkinson's disease, epilepsy, other dementias, or serious brain infections), other than Alzheimer’s Disease

  • Participant must not have a history of alcohol or drug abuse or dependence (except nicotine dependence) within the last 2 years

  • Participant must not have had any of the following within the past year: heart attack; moderate or severe congestive heart failure; hospitalization for chest pain; loss of consciousness due to low blood pressure or unexplained loss of consciousness; known significant structural heart disease or hospitalization for arrhythmia

  • Participant must not have a history of cancer within the last 5 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, or non-progressive prostate cancer or other cancers with low-risk of recurrence or spread

Where to Participate

248 locations are currently available of 248 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.